Cholesterol levels in HIV-HCV infected patients treated with lopinavir/r: Results from the SCOLTA project

Biomedicine and Pharmacotherapy

Volumn 62, Issue 1, 2008, Pages 16-20

  De Socio, Giuseppe Vittorio L ^a   Bonfanti, Paolo ^b   Ricci, Elena ^b   Orofino, Giancarlo ^c   Madeddu, Giordano ^d   Penco, Giovanni ^e   Gianelli, Erika ^b   Martinelli, Canio ^f   Carradori, Silvia ^g   Quirino, Tiziana ^h   Rizzardini, Giuliano ^b  

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c AMEDEO DI SAVOIA HOSPITAL   (Italy)

^d UNIVERSITY OF SASSARI   (Italy)

^e GALLIERA HOSPITAL   (Italy)

^f CAREGGI UNIVERSITY HOSPITAL   (Italy)

^g Sezione di Ferrara   (Italy)

^h BUSTO ARSIZIO HOSPITAL   (Italy)

Author keywords

Antiretroviral therapy; Atherosclerosis; Cardiovascular diseases; Cholesterol; HCV; HIV; Lipids; Lopinavir

Indexed keywords

AMPRENAVIR PHOSPHATE; ATAZANAVIR; CHOLESTEROL; DARUNAVIR; ENFUVIRTIDE; LOPINAVIR PLUS RITONAVIR; TENOFOVIR; TIPRANAVIR; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; DATA ANALYSIS; DRUG WITHDRAWAL; FEMALE; HEALTH SURVEY; HEPATITIS C; HEPATITIS C VIRUS; HOSPITAL DEPARTMENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

ADULT; ANTI-HIV AGENTS; CHOLESTEROL; COHORT STUDIES; DRUG COMBINATIONS; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C, CHRONIC; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRIMIDINONES; RITONAVIR; TRIGLYCERIDES;

EID: 38049015229     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2007.07.012     Document Type: Article

References (32)

1. Carr A., Samaras K., Chisholm D.J., and Cooper D.A. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 351 (1998) 1881-1883
2. Grinspoon S., and Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 352 (2005) 48-62
3. Bonfanti P., Ricci E., De Socio G., Zeme D., Carradori S., Penco G., et al., CISAI Study Group. Metabolic syndrome: a real threat for HIV-positive patients? Results from the SIMONE study. J Acquir Immune Defic Syndr 42 (2006) 128-131
4. Bergersen B.M., Schumacher A., Sandvik L., Bruun J.N., and Birkeland K. Important differences in components of the metabolic syndrome between HIV-patients with and without highly active antiretroviral therapy and healthy controls. Scand J Infect Dis 38 (2006) 682-689
5. Walmsley S., Bernstein B., King M., Arribas J., Beall G., Ruane P., et al. Lopinavir/ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 346 (2002) 2039-2046
6. Bongiovanni M., Bini T., Cicconi P., Landonio S., Meraviglia P., Testa L., et al. Predictive factors of hyperlipidemia in HIV-infected subjects receiving lopinavir/ritonavir. AIDS Res Hum Retroviruses 22 (2006) 132-138
7. de Saint Martin L., Vandhuick O., Guillo P., Bellein V., Bressollette L., Roudaut N., et al. Premature atherosclerosis in HIV positive patients and cumulated time of exposure to antiretroviral therapy (SHIVA study). Atherosclerosis 185 (2006) 361-367
8. Stein J.H. Managing cardiovascular risk in patients with HIV infection. J Acquir Immune Defic Syndr 38 (2005) 115-123
9. Schillaci G., De Socio G.V., Pirro M., Savarese G., Mannarino M.R., Baldelli F., et al. Impact of treatment with protease inhibitors on aortic stiffness in adult patients with human immunodeficiency virus infection. Arterioscler Thromb Vasc Biol 25 (2005) 2381-2385
10. Cicognani C., Malavolti M., Morselli-Labate A.M., Zamboni L., Sama C., and Barbara L. Serum lipid and lipoprotein patterns in patients with liver cirrhosis and chronic active hepatitis. Arch Intern Med 157 (1997) 792-796
11. Maggi G., Bottelli R., Gola D., Perricone G., Posca M., Zavaglia C., et al. Serum cholesterol and chronic hepatitis C. Ital J Gastroenterol 28 (1996) 436-440
12. Siagris D., Christofidou M., Theocharis G.J., Pagoni N., Papadimitriou C., Lekkou A., et al. Serum lipid pattern in chronic hepatitis C: histological and virological correlations. J Viral Hepat 13 (2006) 56-61
13. Polgreen P.M., Fultz S.L., Justice A.C., Wagner J.H., Diekema D.J., Rabeneck L., et al. Association of hypocholesterolaemia with hepatitis C virus infection in HIV-infected people. HIV Med 5 (2004) 144-150
14. Cooper C.L., Mills E., and Angel J.B. Mitigation of antiretroviral-induced hyperlipidemia by hepatitis C virus co-infection. AIDS 21 (2007) 71-76
15. Lapadula G., Torti C., Paraninfo G., Castelnuovo F., Uccelli M.C., Costarelli S., et al., EPOKa-A Study Group of the MASTER Cohort. Influence of hepatitis C genotypes on lipid levels in HIV-positive patients during highly active antiretroviral therapy. Antivir Ther 11 (2006) 521-527
16. De Socio G.V., Martinelli L., Morosi S., Fiorio M., Roscini A.R., Stagni G., et al. Is estimated cardiovascular risk higher in HIV-infected patients than in the general population?. Scand J Infect Dis 39 (2007) 805-812
17. Bonfanti P., Martinelli C., Ricci E., Carradori S., Parruti G., Armignacco O., et al. An Italian approach to postmarketing monitoring: preliminary results from the SCOLTA (Surveillance Cohort Long-Term Toxicity Antiretrovirals) project on the safety of lopinavir/ritonavir. J Acquir Immune Defic Syndr 39 (2005) 317-320
18. Anastos K., Lu D., Shi Q., Tien P.C., Kaplan R.C., Hessol N.A., et al. Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens. J Acquir Immune Defic Syndr 45 (2007) 34-42
19. Ishizaka N., Ishizaka Y., Takahashi E., Tooda E., Hashimoto H., Nagai R., et al. Association between hepatitis C virus seropositivity, carotid-artery plaque, and intima-media thickening. Lancet 359 (2002) 133-135
20. Vassalle C., Masini S., Bianchi F., and Zucchelli G.C. Evidence for association between hepatitis C virus seropositivity and coronary artery disease. Heart 90 (2004) 565-566
21. Arcari C.M., Nelson K.E., Netski D.M., Nieto F.J., and Gaydos C.A. No association between hepatitis C virus seropositivity and acute myocardial infarction. Clin Infect Dis 43 (2006) e53-e56
22. Momiyama Y., Ohmori R., Kato R., Taniguchi H., Nakamura H., and Ohsuzu F. Lack of any association between persistent hepatitis B or C virus infection and coronary artery disease. Atherosclerosis 181 (2005) 211-213
23. Libby P. Inflammation in atherosclerosis. Nature 420 (2002) 868-874
24. Verschuren W.M., Jacobs D.R., Bloemberg B.P., Kromhout D., Menotti A., Aravanis C., et al. Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study. JAMA 274 (1995) 131-136
25. Libby P., and Theroux P. Pathophysiology of coronary artery disease. Circulation 111 (2005) 3481-3488
26. Dressman J., Kincer J., Matveev S.V., Guo L., Greenberg R.N., Guerin T., et al. HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent cholesteryl ester accumulation in macrophages. J Clin Invest 111 (2003) 389-397
27. Simons K., and Ikonen E. How cells handle cholesterol. Science 290 (2000) 1721-1726
28. Simons K., and Ehehalt R. Cholesterol, lipid rafts, and disease. J Clin Invest 110 (2002) 597-603
29. Kapadia S.B., Barth H., Baumert T., McKeating J.A., and Chisari F.V. Initiation of hepatitis C virus infection is dependent on cholesterol and cooperativity between CD81 and scavenger receptor B type I. J Virol 81 (2007) 374-383
30. Scarselli E., Ansuini H., Cerino R., Roccasecca R.M., Acali S., Filocamo G., et al. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J 21 (2002) 5017-5025
31. Mujawar Z., Rose H., Morrow M.P., Pushkarsky T., Dubrovsky L., Mukhamedova N., et al. Human immunodeficiency virus impairs reverse cholesterol transport from macrophages. PLoS Biol 4 (2006) e365
32. Gonzalez-Garcia J.J., Mahillo B., Hernandez S., Pacheco R., Diz S., Garcia P., et al. Prevalences of hepatitis virus co-infection and indications for chronic hepatitis C virus treatment and liver transplantation in Spanish HIV-infected patients. The GESIDA 29/02 and FIPSE 12185/01 Multicenter Study. Enferm Infecc Microbiol Clin 23 (2005) 340-348